Laura Johnston
Academic Appointments
- Associate Professor - Med Center Line, Medicine - Blood & Marrow Transplantation
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Blood and Marrow Transplant Clinic 875 Blake Wilbur Dr Clinic E Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 498-5030
- Academic Offices
Personal Information EmailNot for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Blood and Marrow Transplant
- Cancer> Hematology
- Blood and Marrow Transplantation
- Hematology
- Graft-Versus-Host Disease
Scientific Focus
Current Research Interests
I conduct and develop clinical research trials in allogeneic and autologous hematopoietic cell transplantation (HCT) for hematologic malignancies: acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), myeloproliferative disease, non-Hodgkin lymphoma (NHL), Hodgkin disease, myelodysplasia and aplastic anemia.
A specific interest is graft versus host disease (GVHD), exploring prevention and treatment of acute and chronic GVHD via clinical trials. The objectives of the GVHD trials are to reduce the incidence of GVHD, successfully treat acute and chronic GVHD, identify modalities or agents with more tolerable toxicity profiles and ultimately improve morbidity and mortality of affected patients. To this end, I have established a chronic GVHD clinic within the Stanford BMT division which aids in prospectively identifiing appropriate patients for clinical trials. The chronic GVHD clinic allows comprehensive evaluation and treatment for allogeneic BMT patients with new or progressive CGVHD. Through a multidisciplinary approach with my interested colleagues, I hope to impact the formidable effects GVHD has on the quality of life of the post-allogeneic transplant patient.
Other interests include unrelated donor HCT exploring alternate preparative regimens or graft sources as well as HLA typing.
Clinical Trials
- Recruiting TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD
- Not Recruiting Transplantation for Patients With Chronic Lymphocytic Leukemia
- Recruiting Allogeneic Transplantation Using TL1 & ATG for Older Patients With Hematologic Malignancies
- Recruiting Double Cord Versus Haploidentical (Blood and Marrow Transplant Clinical Trials Network #1101)
- Not Recruiting Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Publications
- Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. Biol Blood Marrow Transplant. 2012; (1): 125-33
- Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood. 2012; (25): 6145-54
- Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplant. 2012; (4): 581-8
- A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood. 2011; (15): 4070-8
- Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011; (11): 1679-87
- Early CMV viremia is associated with impaired viral control following nonmyeloablative hematopoietic cell transplantation with a total lymphoid irradiation and antithymocyte globulin preparative regimen. Biol Blood Marrow Transplant. 2011; (5): 693-702
Help
Trial Administration